Ling Zhang

Ling Zhang

Dr. Ling Zhang is a Senior Technical Expert and Lead of Multi-Cancer Screening Technology at Alibaba DAMO Academy Medical AI Lab. He pioneered the globally original “non-contrast CT + AI” approach for multi-cancer screening, enabling the identification of multiple major cancers through a single non-contrast CT scan. Ling Zhang and his team leveraged this technology to first overcome the early screening challenge for pancreatic cancer, the deadliest cancer. Their research was published in the top-tier medical journal Nature Medicine, which described the work as “AI and imaging-based cancer screening: getting ready for prime time.” The work was also recognized as one of the five major highlights in the fields of science and medicine in Stanford University’s “2024 AI Index Report.”

This technology has been clinically piloted in several hospitals in Zhejiang and Shanghai, screening over 100,000 individuals and discovering more than 20 clinically missed pancreatic cancer patients. Building on their success with pancreatic cancer, Ling Zhang and his team are advancing towards gastric, esophageal, and colorectal cancers, making significant progress toward the goal of multi-cancer screening.

Dr. Ling Zhang graduated from Zhejiang University and has previously worked at the University of Iowa, the National Institutes of Health, NVIDIA, and PAII Inc. He joined Alibaba DAMO Academy Medical AI Laboratory in 2021. Ling Zhang serves as the area chair of the MICCAI field and was nominated for the Best Paper Award at MICCAI 2020. His contributions to AI in oncology have been published in journals such as Annals of Surgery, Clinical Cancer Research, and Radiology.

Share this speaker
Share This Speaker
  • Organization
    Alibaba DAMO Academy Medical AI Lab
  • Profession
    Senior Technical Expert and Lead of Multi-Cancer Screening Technology
Related sessions
In person
9 July 2025
15:40 - 16:00
EST - New York
CST - Beijing
PST - Los Angeles
AWST - Perth, Australia